HUP0500722A2 - Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén - Google Patents

Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén

Info

Publication number
HUP0500722A2
HUP0500722A2 HU0500722A HUP0500722A HUP0500722A2 HU P0500722 A2 HUP0500722 A2 HU P0500722A2 HU 0500722 A HU0500722 A HU 0500722A HU P0500722 A HUP0500722 A HU P0500722A HU P0500722 A2 HUP0500722 A2 HU P0500722A2
Authority
HU
Hungary
Prior art keywords
virus
mutant
subject
mutation
production
Prior art date
Application number
HU0500722A
Other languages
English (en)
Inventor
Zhen Fang Fu
Original Assignee
The University of Georgia Research Foundation, Inc@Á
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Georgia Research Foundation, Inc@Á filed Critical The University of Georgia Research Foundation, Inc@Á
Publication of HUP0500722A2 publication Critical patent/HUP0500722A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgyát egy mutáns vírus képezi, ami a vírus egy vagy többfehérjéjének foszforilezési helyén mutációt hordoz, amely mutáció avírus attenuációját okozza, és ennek következtében ebből egy jobbvakcinakészítmény állítható elő. A találmány tárgyát képezik továbbáolyan vakcinakészítmények, amik tartalmazzák a mutáns vírust, valaminta találmány tárgyát képezik az immunválasz előállítási módszerei, ésaz emlősök megvédése a veszettségvírus-fertőzéstől. A találmánytárgyát képezik a mutáns vírus és mutáns virális fehérjék előállításimódszerei, beleértve a mutáns vírus előállítását egy olyangazdasejtben, amely a mutáns virális fehérjének megfelelő vad típusúfehérjét termeli vagy éppen túltermeli, ami komplementálja a többivirális fehérjét, oly módon, hogy a mutáns vírusrészecske termeléseoptimalizálva van. A találmány tárgyát képezik továbbá azok agazdasejtek, amelyekben a vírustermelés optimalizálva van, valamintazok a vakcinakészítmények, amelyek tartalmazzák a virális fehérjéket,önmagukban, vagy az intakt vírussal kombinálva, és az eljárások,amikkel immunválaszt lehet indukálni, vagy meg lehet védeni egy emlősta fertőzéstől. A találmány tárgyát képezik továbbá a vektorok,amelyekkel egy gént be lehet juttatni egy emberi vagy állati sejtbe,valamint ezek bejuttatási módszerei.
HU0500722A 2001-07-20 2002-07-22 Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén HUP0500722A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33135401P 2001-07-20 2001-07-20
PCT/US2002/023108 WO2003046506A2 (en) 2001-07-20 2002-07-22 Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies

Publications (1)

Publication Number Publication Date
HUP0500722A2 true HUP0500722A2 (hu) 2005-11-28

Family

ID=23293602

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500722A HUP0500722A2 (hu) 2001-07-20 2002-07-22 Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén

Country Status (17)

Country Link
US (3) US6706523B2 (hu)
EP (1) EP1434862A4 (hu)
JP (1) JP2005510249A (hu)
KR (1) KR20040029377A (hu)
CN (1) CN100346826C (hu)
AU (1) AU2002365029A1 (hu)
BR (1) BR0211342A (hu)
CA (1) CA2454397A1 (hu)
CO (1) CO5560623A2 (hu)
HR (1) HRP20040078A2 (hu)
HU (1) HUP0500722A2 (hu)
MX (1) MXPA04000589A (hu)
NZ (1) NZ531025A (hu)
PL (1) PL371967A1 (hu)
WO (1) WO2003046506A2 (hu)
YU (1) YU6304A (hu)
ZA (1) ZA200400340B (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706523B2 (en) * 2001-07-20 2004-03-16 University Of Georgia Research Foundation, Inc. Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS
MX343109B (es) * 2004-04-09 2016-10-25 Wyeth * Atenuacion sinergistica del virus de la estomatitis vesicular, vectores de los mismos y composiciones inmunogenicas de los mismos.
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
CN100341571C (zh) * 2005-09-16 2007-10-10 孙介光 一种治疗肿瘤的药物及该药物在制备治疗肿瘤药物中应用
WO2007047459A1 (en) * 2005-10-14 2007-04-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus vector systems and compositions and methods thereof
CN104059890A (zh) * 2005-12-14 2014-09-24 乔治亚大学研究基金公司 狂犬病疫苗
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
CN102159240B (zh) * 2008-09-17 2014-12-24 美国政府健康及人类服务部，疾病控制和预防中心 基于狂犬病毒的重组免疫避孕组合物及其使用方法
US10849975B2 (en) 2011-02-03 2020-12-01 Thomas Jefferson University Multivalent vaccines for rabies virus and filoviruses
CN102205119B (zh) * 2011-04-12 2012-05-30 广州市华南农大生物药品有限公司 狂犬病灭活抗原及其制备方法
KR101479668B1 (ko) * 2012-07-31 2015-01-12 대한민국 광견병 바이러스 유전자를 발현하는 재조합 아데노바이러스 및 이를 포함하는 광견병의 예방 또는 치료용 백신 조성물
CN106929482A (zh) * 2015-12-31 2017-07-07 北京大学 定点突变的流感病毒、其活疫苗及其制备方法和应用
KR20170002590U (ko) 2016-01-08 2017-07-18 최문규 제조와 포장이 용이한 일회용 위생장갑
EP4104854A3 (en) 2016-04-04 2023-03-08 The United States of America as represented by the Secretary of the Department of Health and Human Services Multivalent vaccines for rabies virus and coronaviruses
WO2017200790A1 (en) * 2016-05-20 2017-11-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Real-time reverse transcriptase-polymerase chain reaction assay with modified probe for the diagnosis of rabies viruses and other lyssaviruses
GB201706945D0 (en) * 2017-05-02 2017-06-14 Medical Res Council Self-inactivating viral vector
US20230398201A1 (en) * 2020-11-03 2023-12-14 Thomas Jefferson University Gene shuffled lyssavirus vaccine
WO2022178307A1 (en) * 2021-02-19 2022-08-25 Beam Therapeutics Inc. Recombinant rabies viruses for gene therapy
CN114957408B (zh) * 2021-02-24 2024-04-23 东莞博盛生物科技有限公司 一种狂犬病毒的preG改性蛋白及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2693655B1 (fr) * 1992-07-20 1994-10-14 Virbac Vaccin antirabique avirulent.
US5583735A (en) 1994-01-18 1996-12-10 Hollingsead International, Inc. Aircraft video monitor deployment and retraction apparatus
PT702085E (pt) * 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6719881B1 (en) 1998-09-22 2004-04-13 Charles R. Hunter Acid colloid in a microparticle system used in papermaking
EP1131414B1 (en) * 1998-11-27 2007-03-07 Intervet International BV Stable, attenuated rabies virus mutants and live vaccines thereof
US6706523B2 (en) * 2001-07-20 2004-03-16 University Of Georgia Research Foundation, Inc. Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS

Also Published As

Publication number Publication date
NZ531025A (en) 2005-08-26
US7419816B2 (en) 2008-09-02
MXPA04000589A (es) 2005-06-17
CA2454397A1 (en) 2003-06-05
EP1434862A4 (en) 2005-04-06
US20030099671A1 (en) 2003-05-29
US6706523B2 (en) 2004-03-16
HRP20040078A2 (en) 2004-08-31
CN1635905A (zh) 2005-07-06
CO5560623A2 (es) 2005-09-30
US20070178555A1 (en) 2007-08-02
CN100346826C (zh) 2007-11-07
ZA200400340B (en) 2004-08-18
JP2005510249A (ja) 2005-04-21
WO2003046506A3 (en) 2004-04-22
PL371967A1 (en) 2005-07-11
US20040208900A1 (en) 2004-10-21
KR20040029377A (ko) 2004-04-06
YU6304A (sh) 2006-08-17
WO2003046506A2 (en) 2003-06-05
US7544791B2 (en) 2009-06-09
BR0211342A (pt) 2005-05-03
AU2002365029A1 (en) 2003-06-10
EP1434862A2 (en) 2004-07-07

Similar Documents

Publication Publication Date Title
HUP0500722A2 (hu) Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén
Suter et al. BAC-VAC, a novel generation of (DNA) vaccines: a bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
CN104271745A (zh) 用于治疗巨细胞病毒的组合物和方法
BR9205771A (pt) Vetor de vírus recombinantes e processo para a fabricaçao do mesmo
Del Fresno et al. The bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity
Tang et al. Vaccines as a strategy to control trichinellosis
Pishesha et al. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants
Khairkhah et al. Immunological investigation of a multiepitope peptide vaccine candidate based on main proteins of SARS-CoV-2 pathogen
HUP9901005A2 (hu) Herpeszvírusok RFHV/KSHV-alcsaládjába tartozó vírusokból származó glikoprotein-B
KR890700030A (ko) 인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법
HUP9801334A2 (hu) A 18-as típusú humán papillomavírust kódoló DNS
Karpenko et al. Results of phase I clinical trials of a combined vaccine against HIV-1 based on synthetic polyepitope immunogens
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
Zhao et al. Construction of the recombinant vaccine based on T-cell epitope encoding Der p1 and evaluation on its specific immunotherapy efficacy
CN103890004A (zh) 由具有特定免疫显性表位的婴儿利什曼虫pfr1蛋白片段组成的嵌合分子可用于抗利什曼病的免疫疗法
CA1270438A (en) Influenza vaccine
CN113416237B (zh) 一种用于诱导免疫的表位多肽与病毒载体组合
Miles Viruses of parasitic protozoa
WO2000077177A3 (en) Isolation of a human retrovirus
EP0542895B1 (en) Cross-reactive influenza a immunization
NO20005482L (no) Rekombinant virus og anvendelser derav samt vaksine som omfatter nevnte virus.
Sun et al. Characterization of CSF2A fusion gene and its effect on Epstein–Barr virus–positive tumor cells

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees